Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...
Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.
CVS Caremark and Express Scripts, along with GoodRx and others, are accused of working together to suppress reimbursements to independent pharmacies in at least three class-action lawsuits. Also, Hims ...
Hims & Hers is revolutionizing healthcare with affordable, convenient telehealth services, leading to a 260% stock increase in the last year. The company benefits from GLP-1 drug sales and is ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Hims & Hers Health will join the S&P SmallCap 600 prior to the opening of trading on Wednesday. Hims & Hers will replace Vector Group, which is being acquired by JT Group. Hims & Hers Health Inc ...
Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback